CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease

NCT06347718 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus
Systemic Sclerosis
Dermatomyositis
Polymyositis

Interventions

DRUG: anti-CD19 CAR T cell therapy

Sponsor

Miltenyi Biomedicine GmbH